Loan to an Equity Method Investee |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Loan to an Equity Method Investee [Abstract] | |
| LOAN TO AN EQUITY METHOD INVESTEE | NOTE 6 - LOAN TO AN EQUITY METHOD INVESTEE
On October 8, 2024, the Company and certain other investors (the “Additional Holders of Note B”) entered into a refinancing agreement with Scilex, pursuant to which the parties were granted rights to receive royalties from certain Scilex products. In connection with these rights, the Additional Holders of Note B incorporated RoyaltyVest Ltd. (“RoyaltyVest”) in the British Virgin Islands on January 2, 2025, and on February 12, 2025, transferred 50% of its issued and outstanding capital stock to the Company. As of September 30, 2026, the fair value of the loan to RoyaltyVest was $4, compared to $553 as of December 31, 2025. During the nine and three months ended September 30, 2026, the Company recognized losses of $549 and $444, respectively, from the revaluation of the loan, which are presented within “Financial income, net” (see Note 15).
There are no guarantees or commitments related to RoyaltyVest. Since the loan is measured at fair value, it is not subject to impairment assessment, and the decrease in its carrying value reflects changes in its fair value. In addition to its original investment, the Company uses RoyaltyVest as a potential investment vehicle for additional transactions conducted in collaboration with the other shareholders.
As such, on March 4, 2025, the Company entered into a loan agreement with RoyaltyVest pursuant to which the Company made a loan to RoyaltyVest in the amount of $7,000 to purchase shares of BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel”). The loan is non-interest bearing and is non-recourse to the BioXcel shares, with repayment of principal and yield to be made from the proceeds of sales of BioXcel shares and warrants. The Company has elected the fair value option to measure the loan and accordingly presents it at fair value. During the year ended December 31, 2025, the Company received $6,251 of principal repayments from BioXcel share sales. No principal repayments were received during the nine months ended September 30, 2026. |